Catalog No.
DHJ57503
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1, kappa
Applications
Research Grade Biosimilar
Target
CD318, Transmembrane and associated with src kinases, TRASK, Subtractive immunization M plus HEp3-associated 135 kDa protein, SIMA135, Membrane glycoprotein gp140, CUB domain-containing protein 1, CDCP1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9H5V8
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
38 E11#
Note
For research use only. Not suitable for clinical or therapeutic use.
Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model., PMID:18483259
The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation., PMID:19349359
Functional role of cell surface CUB domain-containing protein 1 in tumor cell dissemination., PMID:19671673
Inhibition of tumor metastasis: functional immune modulation of the CUB domain containing protein 1., PMID:19916495
CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis., PMID:21220330
The SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motility., PMID:21725358
Cell-surface markers for the isolation of pancreatic cell types derived from human embryonic stem cells., PMID:21804561
Infrared spectral signatures of CDCP1-induced effects in colon carcinoma cells., PMID:22034616
The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration., PMID:22315226
Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers., PMID:23105007
Stratum basale keratinocyte expression of the cell-surface glycoprotein CDCP1 during epidermogenesis and its role in keratinocyte migration., PMID:23121233
In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling., PMID:23208492
Structural requirements for cub domain containing protein 1 (CDCP1) and Src dependent cell transformation., PMID:23300860
Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy., PMID:24055141
Global phosphotyrosine proteomics identifies PKCδ as a marker of responsiveness to Src inhibition in colorectal cancer., PMID:24260357
EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface., PMID:24681947
CDCP1 identifies a CD146 negative subset of marrow fibroblasts involved with cytokine production., PMID:25275584
The tyrosine phosphatase SHP2 associates with CUB domain-containing protein-1 (CDCP1), regulating its expression at the cell surface in a phosphorylation-dependent manner., PMID:25876044
Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer., PMID:25892239
Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance., PMID:25893298
Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling., PMID:26227951
Dysregulated expression of cell surface glycoprotein CDCP1 in prostate cancer., PMID:26497208
Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer., PMID:26882065
CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment., PMID:27495374
Cell-Surface Protein Profiling Identifies Distinctive Markers of Progenitor Cells in Human Skeletal Muscle., PMID:27509136
Expression of CDCP1 and ADAM12 in the ovarian cancer microenvironment., PMID:27685922
Hepatic stem cells with self-renewal and liver repopulation potential are harbored in CDCP1-positive subpopulations of human fetal liver cells., PMID:29402311
Clinical and experimental evidence for targeting CD6 in immune-based disorders., PMID:29526637
CUB Domain-containing Protein 1 (CDCP1) Is Down-regulated by Active Hexose-correlated Compound in Human Pancreatic Cancer Cells., PMID:30396925
Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma., PMID:32226543
Attenuation of Murine Collagen-Induced Arthritis by Targeting CD6., PMID:32307907
Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer., PMID:32341034
Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer-Letter., PMID:33060289
CD6 is a target for cancer immunotherapy., PMID:33497367
Contemporary Lung Cancer Screening and the Promise of Blood-Based Biomarkers., PMID:34252039
Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer., PMID:34448393
Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer., PMID:34621145
Cleaved CDCP1 marks the spot: a neoepitope for RAS-driven cancers., PMID:35166242
Antibodies Against Cleaved CDCP1 Show Activity in RAS-Mutant Tumors., PMID:35373280
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease., PMID:35604681
CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy., PMID:36276654
Keratinocyte-induced costimulation of human T cells through CD6 - but not CD2 - activates mTOR and prevents oxidative stress., PMID:36353616
Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer., PMID:36648492
Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer., PMID:37468417
Activation of Cytotoxic Lymphocytes Through CD6 Enhances Killing of Cancer Cells., PMID:37886483
CD6 and Its Interacting Partners: Newcomers to the Block of Cancer Immunotherapies., PMID:38139340
Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells., PMID:38280067
Quantitative Membrane Proteomics for Discovery of Actionable Drug Targets at the Surface of RAS-Driven Human Cancer Cells., PMID:39052212
Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2- Breast Cancers., PMID:39869307
Itolizumab regulates activating and inhibitory signals on effector cells, improving their cytotoxicity against CD318+ tumor cell lines., PMID:40391211
For research use only. Not for human or drug use.
